EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Blood-tumor barrier in focus - investigation of glioblastoma-induced effects on the blood-brain barrier

Sanjana Mathew-Schmitt, Matthias Peindl, Philipp Neundorf, Gudrun Dandekar, Marco Metzger, Vera Nickl, Antje Appelt-Menzel

Journal of Neuro-Oncology · 2024

DOI: 10.1007/s11060-024-04760-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Sanjana Mathew-Schmitt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chair Tissue Engineering and Regenerative Medicine, University Hospital Würzburg, Röntgenring 11, 97070, Würzburg, Germany. Hauptthemen laut MEDLINE: Glioblastoma, Blood-Brain Barrier, Brain Neoplasms, Spheroids, Cellular. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Würzburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Glioblastoma (GBM) is the most prevalent, malignant, primary brain tumor in adults, characterized by limited treatment options, frequent relapse, and short survival after diagnosis. Until now, none of the existing therapy and treatment approaches have proven to be an effective cure. The availability of predictive human blood-tumor barrier (BTB) test systems that can mimic in-vivo pathophysiology of GBM would be of great interest in preclinical research. Here, we present the establishment of a new BTB in-vitro test system combining GBM spheroids and BBB models derived from human induced pluripotent stem cells (hiPSCs).

Methods

We co-cultured hiPSC-derived brain capillary endothelial-like cells (iBCECs) with GBM spheroids derived from U87-MG and U373-MG cell lines in a cell culture insert-based format. Spheroids were monitored over 168 hours (h) of culture, characterized for GBM-specific marker expression and treated with standard chemotherapeutics to distinguish inhibitory effects between 2D mono-culture and 3D spheroids. GBM-induced changes on iBCECs barrier integrity were verified via measurement of transendothelial electrical resistance (TEER), immunocytochemical staining of tight junction (TJ) proteins claudin-5 and occludin as well as the glucose transporter-1 (Glut-1). GBM-induced secretion of vascular endothelial growth factor (VEGF) was additionally quantified.

Results

Our hypothesis was validated by reduced expression of TJ proteins, occludin and claudin-5 together with significant barrier breakdown in iBCECs after only 24 h of co-culture, demonstrated by reduction in TEER from 1313 ± 265 Ω*cm 2 to 712 ± 299 Ω*cm 2 (iBCECs + U87-MG) and 762 ± 316 Ω*cm 2 (iBCECs + U373-MG). Furthermore, 3D spheroids show more resistance to standard GBM chemotherapeutics in-vitro compared to 2D cultures.

Conclusions

We demonstrate the establishment of a simplified, robust in-vitro BTB test system, with potential application in preclinical therapeutic screening and in studying GBM-induced pathological changes at the BBB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBlood-Brain BarrierBrain NeoplasmsSpheroids, CellularCoculture TechniquesHumansInduced Pluripotent Stem CellsEndothelial CellsCell Line, Tumor

Stichwörter der Autor:innen

Blood-brain barrier (BBB)Blood-tumor barrier (BTB)Glioblastoma (GBM)Human induced pluripotent stem cells (hiPSCs)In-vitro modelsPreclinical testingSpheroids

Autor:innen und Institutionen

  • Chair Tissue Engineering and Regenerative Medicine, University Hospital Würzburg, Röntgenring 11, 97070, Würzburg, Germany.
  • Translational Centre Regenerative Therapies TLC-RT, Fraunhofer Institute for Silicate Research ISC, Röntgenring 11, 97070, Würzburg, Germany.
  • Section Experimental Neurosurgery, Department of Neurosurgery, University Hospital Würzburg, Josef-Schneider-Straße 11, 97080, Würzburg, Germany.
  • Chair Tissue Engineering and Regenerative Medicine, University Hospital Würzburg, Röntgenring 11, 97070, Würzburg, Germany. antje.appelt-menzel@uni-wuerzburg.de.
  • Translational Centre Regenerative Therapies TLC-RT, Fraunhofer Institute for Silicate Research ISC, Röntgenring 11, 97070, Würzburg, Germany. antje.appelt-menzel@uni-wuerzburg.de.

Förderung

  • Universitätsklinikum Würzburg

Zitieren

APA

Mathew-Schmitt, S., Peindl, M., Neundorf, P., Dandekar, G., Metzger, M., Nickl, V., & Appelt-Menzel, A. (2024). Blood-tumor barrier in focus - investigation of glioblastoma-induced effects on the blood-brain barrier. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04760-w

Vancouver

Mathew-Schmitt S, Peindl M, Neundorf P, Dandekar G, Metzger M, Nickl V, et al. Blood-tumor barrier in focus - investigation of glioblastoma-induced effects on the blood-brain barrier. Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04760-w

BibTeX
@article{MathewSchmitt2024,
  author = {Mathew-Schmitt, Sanjana and Peindl, Matthias and Neundorf, Philipp and Dandekar, Gudrun and Metzger, Marco and Nickl, Vera and Appelt-Menzel, Antje},
  title = {Blood-tumor barrier in focus - investigation of glioblastoma-induced effects on the blood-brain barrier},
  journal = {Journal of Neuro-Oncology},
  year = {2024},
  doi = {10.1007/s11060-024-04760-w}
}
Kostenlos starten →